SAR 161271

Drug Profile

SAR 161271

Alternative Names: SAR161271

Latest Information Update: 03 Aug 2010

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antihyperglycaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 30 Jul 2010 Discontinued - Phase-I/II for Type-1 diabetes mellitus in Germany (SC)
  • 15 Jun 2010 Sanofi-aventis completes a phase I/II trial in Type-1 diabetes mellitus in Germany
  • 19 Jan 2010 Phase-I/II clinical trials in Type-1 diabetes mellitus in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top